Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00475150 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 |
| clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01567059 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 34 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Feb 14, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00416624 | Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy | completed | Phase 2 | 239 | Mayo ClinicOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00815321 | Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy | completed | Phase 2 | 11 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01038635 | 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 94 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00528398 | Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 111 | City of Hope Medical CenterOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00313586 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 2 | 197 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2017 | clinicaltrials |
| NCT02042911 | Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 10 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL(CCFMPCA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT00003840 | DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT00072579 | Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment | completed | Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT00082940 | Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01520922 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 2 | 99 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 19, 2017 | clinicaltrials |
| NCT00536341 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 64 | SCRI Development Innovations, LLCOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2017 | clinicaltrials |
| NCT03022747 | Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol | unknown | Phase 2 | 60 | Vastra Gotaland RegionOTHER_GOV | 2 | Jan 16, 2017 | clinicaltrials |
| NCT01709396 | ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS(ED-TBI) | suspended | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00548431 | NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia | completed | Phase 2 | 38 | Rigshospitalet, DenmarkOTHER | 2 | Jan 9, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00391989 | Treatment of Adult Ph+ LAL With BMS-354825 | completed | Phase 2 | 53 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2017 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT03005392 | Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 24 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01681563 | Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 47 | Niguarda HospitalOTHER | 1 | Dec 28, 2016 | clinicaltrials |
| NCT00136409 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01600053 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | terminated | Phase 2 | 11 | Thomas KippsOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01733953 | Statin Therapy in Young Adult Survivors of Childhood Cancer | completed | Phase 2 | 27 | University of MinnesotaOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT00512252 | AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia(AMD3100+MEC) | completed | Phase 1 / Phase 2 | 52 | Washington University School of MedicineOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT00003829 | Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 34 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT00005829 | Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia | completed | Phase 2 | 22 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02420938 | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01401322 | Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00683046 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 2 | 204 | University of ChicagoOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT01459211 | Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)(LenD) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 8, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Feb 15, 2017source: clinicaltrials